PRecision Interventions for SMoking in the SCCS

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

May 18, 2018

Primary Completion Date

April 11, 2019

Study Completion Date

April 25, 2019

Conditions
Tobacco Use Cessation
Interventions
DRUG

Nicotine patch

FDA-approved smoking cessation pharmacotherapy

DRUG

Varenicline

FDA-approved smoking cessation pharmacotherapy

GENETIC

Nicotine metabolism

Information on nicotine metabolism will be used to inform selection of medication.

GENETIC

Genetically-informed lung cancer risk score

This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.

BEHAVIORAL

"NCI Clearing the Air"

A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.

Trial Locations (1)

37203

Vanderbilt University Medical Center, Nashville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Meharry Medical College

OTHER

collaborator

Tennessee State University

OTHER

lead

Vanderbilt University Medical Center

OTHER